This includes those who are immunosuppressed, or who have other conditions such as heart disease, respiratory disease, diabetes or neurological disorders.
The agency’s latest guidance recommends the use of Pfizer’s Paxlovid (tirmatrelvir plus ritonavir), GSK’s Xevudy (sotrovimab) and Roche’s RoActemra (tocilizumab).
Paxlovid has been recommended for adults who do not need supplemental oxygen for COVID-19 and are at an increased risk for progression to severe disease, while Xevudy is recommended for the same group in cases where Paxlovid is contraindicated or unsuitable…
